Mickisch, G. H. J., Escudier, B., Walzer, S., & Nuijten, M. (2010). Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. Nature Publishing Group.
シカゴスタイル引用形Mickisch, G H J., B. Escudier, S. Walzer, , M. Nuijten. Reply: Costs of Managing Adverse Events in the Treatment of First-line Metastatic Renal Cell Carcinoma: Bevacizumab in Combination With Interferon-α2a Compared With Sunitinib. Nature Publishing Group, 2010.
MLA引用形式Mickisch, G H J., B. Escudier, S. Walzer, , M. Nuijten. Reply: Costs of Managing Adverse Events in the Treatment of First-line Metastatic Renal Cell Carcinoma: Bevacizumab in Combination With Interferon-α2a Compared With Sunitinib. Nature Publishing Group, 2010.